“…Accordingly, reports from several groups that levels of AT8 antibody, a biomarker of tau-P, are elevated in postmortem brain in illicit opioid users, even in users under age 30 (Ramage et al, 2005;Anthony et al, 2010;Kovacs et al, 2015;Flanagan et al, 2018), as are levels of APP (Ramage et al, 2005), suggest that individuals with opioid use disorder are at increased risk for developing AD/ADRD. Opioids increase oxidative stress in brain, blood, and body (Zhou et al, 2000;Qiusheng et al, 2005;Arana et al, 2006;Xu et al, 2006;Pereska et al, 2007;Pérez-Casanova et al, 2008;Doyle et al, 2009;Ndengele et al, 2009;Abdel-Zahar et al, 2010;Kovatsi et al, 2010aKovatsi et al, , 2010bCemek et al, 2011;Gutowicz et al, 2011;Sumathi et al, 2011;Deng et al, 2012;Ghazavi et al, 2013;Soykut et al, 2013;Fan et al, 2015;Motaghinejad et al, 2015;Samarghandian et al, 2015;Yun et al, 2015Yun et al, , 2017Lauro et al, 2016;Najafi et al, 2017;Mansouri et al, 2018) and thus could increase Aβ and tau-P syntheses and accumulations via multiple mechanisms described above. In neuronal culture, morphine upregulates GSK3β activity (Masvekar et al, 2015), which could contribute to increased tau-P levels in opioid users.…”